Lilly(US:LLY) GLP1减重宝典·2025-06-24 10:06Core Viewpoint - The recent phase II clinical trial results from Eli Lilly demonstrate significant efficacy in weight management when combining Bimagrumab with Semaglutide (Wegovy), with participants experiencing an average weight loss of 22.1% over 48 weeks, compared to 15.7% with Semaglutide alone [2][4]. Group 1 - The combination therapy shows a synergistic effect, leading to greater weight loss and preservation of lean body mass, which is particularly important for populations at risk of sarcopenia [4]. - Bimagrumab, an antibody targeting activin receptor type II, helps protect muscle quality during weight loss, addressing a common issue with GLP-1 medications that can lead to muscle loss [2][4]. - The research highlights the need for a multidisciplinary approach to obesity treatment, integrating medication, lifestyle changes, and psychological support [5]. Group 2 - Eli Lilly is also advancing clinical trials for Bimagrumab in combination with Zepbound, a dual-target GLP-1/GIP agonist, expanding treatment options for patients [5]. - The successful results of the phase II trial mark a significant advancement in obesity treatment, potentially leading to a new paradigm in weight management strategies [5]. - This "dual-target, dual-effect" treatment model may become a key breakthrough in personalized and refined weight loss therapies, benefiting millions globally [5].